Commodore Capital Portfolio holdings
Commodore Capital runs funds that back drug developers, from early-stage public companies to late-stage private ones. It aims to fill a gap it sees between traditional venture capital and public market funds. Its thesis is that small biopharma companies, not large drugmakers, drive much of the innovation in areas like genetic medicines and cell therapies. Michael Kramarz and Egen Atkinson, both medical doctors with MBAs, are its managing partners. They indirectly own a majority of the firm, which began operating in 2019. The funds are open to institutions, pension plans, endowments and high net worth individuals.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tango Therapeutics
TNGX
|
+$55.6M |
| 2 |
Editas Medicine
EDIT
|
+$26M |
| 3 |
EyePoint
EYPT
|
+$23.7M |
| 4 |
InflaRx
IFRX
|
+$13.7M |
| 5 |
Assembly Biosciences
ASMB
|
+$11.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nuvalent
NUVL
|
+$78.9M |
| 2 |
Spyre Therapeutics
SYRE
|
+$77.8M |
| 3 |
Relay Therapeutics
RLAY
|
+$72.6M |
| 4 |
Erasca
ERAS
|
+$51.4M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.36% |
| 2 | Financials | 0.64% |
Similar funds
Commodore Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Commodore Capital held 41 positions worth $1.68B, down 2.9% from $1.73B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Commodore Capital withdrew a net $478M in Q2 2026, closing 8 positions and reducing 9 holdings. Its most notable exit was Erasca, an estimated $51.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.
Against the trend, Commodore Capital opened a new position in Tango Therapeutics worth $70.3M.
- Commodore Capital's largest Q2 2026 buy was Tango Therapeutics: 2,250,000 shares worth $70.3M.
- Commodore Capital added most to EyePoint in Q2 2026, an estimated $23.7M increase.
- Commodore Capital's biggest Q2 2026 reduction was Nuvalent, cutting an estimated $78.9M.
- Commodore Capital fully exited Erasca in Q2 2026, selling an estimated $51.4M.
- Commodore Capital's ten largest holdings make up 68% of its $1.68B portfolio in Q2 2026.
- Commodore Capital opened 5 new positions and closed 8 in Q2 2026.
- Commodore Capital's portfolio value fell 2.9% quarter-over-quarter to $1.68B.
Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.